Clinical Trials
28 trialsNCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT02145910 2025-05-02
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
Phase 1 Withdrawn
NCT01657591 2023-01-19
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02818023 2022-01-03
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
University of Pittsburgh
Phase 1 Terminated
NCT01656642 2020-07-21
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
Phase 1 Completed
NCT01897116 2020-05-29
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02608034 2020-02-12
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Genentech, Inc.
Phase 1 Completed
NCT01585415 2019-11-21
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01271803 2019-07-29
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01910181 2019-05-29
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02068079 2019-01-30
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Duke University
Phase 1 Withdrawn
NCT01876641 2018-09-19
ML28604
University of Iowa
Phase 1 Terminated
NCT01943422 2018-04-03
12-107
University of Pittsburgh
Phase 1 Completed
NCT02441465 2017-11-14
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT00405587 2017-08-22
Safety Study of PLX4032 in Patients With Solid Tumors
Plexxikon
Phase 1 Completed
NCT01843738 2017-05-24
Radiation Use During Vemurafenib Treatment
University of Utah
Phase 1 Withdrawn
NCT01611675 2017-04-06
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Massachusetts General Hospital
Phase 1 Terminated
NCT01844674 2017-03-20
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT01765543 2016-12-15
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
Phase 1 Completed
NCT01765556 2016-11-02
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01849666 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01851824 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01519323 2016-10-10
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Hoffmann-La Roche
Phase 1 Terminated
NCT01765569 2015-09-23
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01400451 2015-01-01
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Bristol-Myers Squibb
Phase 1 Terminated
NCT01835184 2014-09-25
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01841463 2014-09-04
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Piramal Enterprises Limited
Phase 1 Suspended